{"id":687,"date":"2025-01-21T15:57:28","date_gmt":"2025-01-21T15:57:28","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=687"},"modified":"2025-06-06T08:55:45","modified_gmt":"2025-06-06T08:55:45","slug":"hidradenitis-suppurutiva","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/dermatology\/hidradenitis-suppurutiva\/","title":{"rendered":"Hidradenitis Suppurutiva"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Biomarkers for evaluating hidradenitis suppurativa (HS)<\/h2>\n \n\n <\/div>\n
\n

Systemic skin diseases with local manifestations, such as Hidradenitis Suppurativa, are characterized by excessive tissue remodeling and immune cell activity. This manifests in painful nodules, abscesses, and draining malodorous tunnels, affecting the patient\u2019s quality of life.<\/p>\n

Tissue-specific biomarkers, quantifying and monitoring epidermal damage, dermal damage and immune cell activity, are\u00a0key advantages\u00a0when understanding the disease mechanisms and complexity in hidradenitis suppurativa, and lead to targeted successful treatments.<\/p>\n

\n

Did you know?<\/h3>\n<\/div>\n
\n

Hidradenitis suppurutiva has several aspects of unment needs. These needs can addressed by utilizing biomarkers to reduce diagnostic delay, closer monitoring of disease activity, define disease heterogeneity, refine drug repurposing and identify novel therapeutic targets.<\/p>\n

Currently a trial-and-error approach is used when treating patients with hidradenitis suppurativa. This could be improved by predictive biomarkers allowing the selection of therapy with a greater reliability of response.<\/p>\n<\/div>\n <\/div>\n

\n

Publications<\/h3>\n